Mathias Karlsson, born 1972, is Calmark's founder and medical advisor for the Company. Member since 2016 and Chairman between 2016 and 2020. Mathias is a doctor and has a doctoral thesis at Karolinska Institutet in the field of perinatal asphyxia. His role today is CEO of Equalis, a provider of external quality assurance systems in laboratory medicine, imaging and functional medicine, and patient-close analysis. Mathias Karlsson is the founder and co-owner of HemCheck Sweden AB. Shareholding in Calmark Sweden AB: 92,700 Class A shares, 997,364 Class B shares and 9,300 warrants (TO).

Kjersti Berg Marthinsen, born 1972, has been a member since 2018 and Chairman of the Board since 2020. Kjersti holds an MSc in Strategy from BI School of Economics in Oslo. She has worked for several years as a consultant both nationally and internationally with assignments in the areas of strategy, organizational development, management and governance. In recent years, she has held various senior positions at the County Council of Värmland, responsible for, among other things, planning and follow-up, development support, innovation support and the county council's commitment to service design and user involvement. In 2018, Kjersti started working at Effect Management Development AB where she is co-owner and vice president. Shareholding in Calmark Sweden AB: 7,050 Class B shares and 1,500 warrants (TO).

‍

Anna-Karin Edstedt Bonamy, born 1974, is a member since 2018. Anna-Karin holds a PhD in paediatrics from Karolinska Institutet since 2008 and is a specialist in paediatric and adolescent medicine since 2009. She has worked as a doctor in neonatal care between 2006 and 2017. In her research, she has led, among other things, the Swedish part of a large European research project (EPICE) on the care of premature babies. Anna-Karin has been Associate Professor of Paediatrics at Karolinska Institutet since 2014 and in 2017 she started working at the e-health company Doctrin, where she is now CEO. Shareholding in Calmark Sweden AB: 12,226 Class B shares and 2,685 warrants (TO).

Stefan Blomsterberg, born 1964, has been a member since 2018. Stefan is educated in the Swedish Armed Forces and has worked with educational development and pedagogy as well as with international armor control. He started working in Medtech in 2002 and has held senior positions within Vitrolife AB, Mölnlycke Healthcare AB, Bioeffect AB and is now CEO of Medfield Diagnostics AB. Shareholding in Calmark Sweden AB: 7,700 Class B shares.